Voriconazole ophthalmic solution is a compounded antifungal eye drop used primarily to treat fungal keratitis, a serious corneal infection that can threaten vision. The drug is only manufactured in systemic formulations (tablets and injectable vials), so the eye drops must be prepared by pharmacies from the injectable product, typically at a 1% concentration.1Clinical Ophthalmology. Clinical utility of voriconazole eye drops in ophthalmic fungal keratitis Because fungal eye infections are relatively uncommon in developed countries but can be devastating when they occur, understanding when and how this medication is used matters for anyone facing a diagnosis or managing treatment.
Why Fungal Keratitis Needs Specialized Treatment
Fungal keratitis is an infection of the cornea caused by fungi rather than bacteria or viruses. It tends to follow trauma to the eye involving plant material or soil, though contact lens wear and prior eye surgery are also risk factors. Unlike bacterial keratitis, which usually responds quickly to antibiotic drops, fungal infections progress more slowly and are harder to treat. The available antifungal eye medications are limited. In many countries, natamycin (a 5% suspension) is the only commercially manufactured antifungal eye drop. That scarcity is exactly why compounded voriconazole eye drops became an important option: voriconazole covers a broad spectrum of fungal species and penetrates well into the deeper layers of the cornea and the interior of the eye.1Clinical Ophthalmology. Clinical utility of voriconazole eye drops in ophthalmic fungal keratitis
How the Eye Drops Are Made
Because no manufacturer sells voriconazole as a ready-made eye drop, hospital and compounding pharmacies prepare it by diluting the commercially available injectable form (sold under the brand name Vfend, among others) in sterile water to achieve a 1% concentration. This process has to follow strict aseptic technique to keep the solution safe for use on the eye. Stability studies have confirmed that these compounded drops hold up well: the drug concentration stays within acceptable limits for at least 90 days when stored frozen at around −20°C, and the solution remains clear, colorless, and free of particles throughout that period.2PubMed. Stability of frozen 1% voriconazole ophthalmic solution Similar findings have been reported using both glass and plastic containers, giving pharmacies some flexibility in packaging.3European Journal of Pharmaceutical Sciences. Stability of frozen 1% voriconazole eye-drops in both glass and innovative containers
For patients, the practical takeaway is that these drops usually arrive frozen and need to be thawed before use, then kept refrigerated. Because they lack the preservatives found in mass-produced eye drops, they have a shorter shelf life once thawed. Your pharmacy or ophthalmologist will give you specific storage instructions, and following them closely matters for both potency and sterility.
What Voriconazole Eye Drops Treat
The primary use is fungal keratitis. The fungi most commonly responsible for corneal infections include species of Aspergillus, Fusarium, and Candida. Voriconazole has meaningful activity against all three groups, though as we will see, its performance varies depending on which organism is involved. When applied topically, the drug reaches concentrations in the aqueous humor (the fluid inside the front of the eye) that exceed the levels needed to inhibit growth of most Candida and Aspergillus species.4PubMed Central. Voriconazole concentration in human aqueous humor and plasma during topical or combined topical and systemic administration for fungal keratitis
Beyond garden-variety fungal keratitis, voriconazole eye drops have been used successfully in more unusual situations. A case report documented resolution of a corneal infection caused by Scopulariopsis brevicaulis, a rare fungus, after LASIK surgery. The infiltrate cleared after about six weeks of topical treatment with fortified 1% voriconazole.5PubMed Central. Keratitis by Scopulariopsis brevicaulis Fungus After LASIK – A Case Report Cases like this highlight the drug’s value when standard antifungals are unlikely to work against an unusual pathogen.
How It Compares to Natamycin
Natamycin is the traditional first-line topical antifungal for keratitis, and the question of whether voriconazole might do better has been tested head-to-head. The Mycotic Ulcer Treatment Trial, a large randomized study, found that natamycin produced significantly better outcomes than voriconazole for filamentous fungal keratitis overall. The advantage was driven heavily by Fusarium infections, where natamycin led to much better visual acuity and far fewer corneal perforations. For non-Fusarium infections, results were similar between the two drugs.6JAMA Ophthalmology. The Mycotic Ulcer Treatment Trial: A Randomized Trial Comparing Natamycin vs Voriconazole
A separate randomized trial reinforced this pattern. Roughly 89% of patients treated with natamycin had healed or resolving ulcers at their last follow-up, compared to about 67% of those on voriconazole. Again, the gap was most pronounced in Fusarium keratitis, while outcomes for Aspergillus keratitis did not differ significantly between the two treatments.7PubMed. Re-appraisal of topical 1% voriconazole and 5% natamycin in the treatment of fungal keratitis in a randomised trial
The upshot is that natamycin tends to be the stronger choice for Fusarium infections, while voriconazole holds its own against Aspergillus and Candida. In practice, many ophthalmologists start natamycin when the organism is unknown and add or switch to voriconazole based on culture results and the clinical response.
Combination Therapy
Rather than choosing one drug or the other, clinicians sometimes use natamycin and voriconazole together. One trial comparing natamycin alone with natamycin plus voriconazole found that the combination enhanced antifungal effect, improved drug sensitivity, and led to better resolution of corneal ulcers.8PubMed Central. Natamycin versus natamycin combined with voriconazole in the treatment of fungal keratitis This dual approach is particularly common in severe or deep infections, where relying on a single agent may not be enough. When the infection is deep-seated, systemic (oral) voriconazole is sometimes added alongside the topical drops to boost drug levels inside the eye.4PubMed Central. Voriconazole concentration in human aqueous humor and plasma during topical or combined topical and systemic administration for fungal keratitis
Side Effects and Tolerability
Topical voriconazole at 1% is generally well tolerated by the eye.1Clinical Ophthalmology. Clinical utility of voriconazole eye drops in ophthalmic fungal keratitis Most patients experience only mild, transient stinging or burning on instillation, the kind of discomfort common to many eye drops. However, a few more notable reactions deserve attention.
Periocular contact dermatitis has been reported. In a case series, two patients being treated for fungal keratitis developed redness, swelling, a burning sensation, and itching around the eye within 48 hours of starting topical voriconazole. Clinical examination showed periocular redness with skin thickening, and a dermatologist confirmed contact dermatitis caused by the drug.9PubMed Central. Periocular contact dermatitis with use of topical voriconazole 1% in mycotic keratitis If you notice an itchy, red, swollen rash around your eye after starting the drops, tell your eye doctor promptly. This type of reaction usually resolves once the drug is stopped, but ignoring it could make the surrounding skin breakdown worse while doing nothing to help the underlying infection.
Because the drops are applied to the surface of the eye and the total dose absorbed into the bloodstream is minimal, the systemic side effects associated with oral or intravenous voriconazole (liver toxicity, visual disturbances, skin sensitivity to sunlight) are not expected with topical use. That said, systemic voriconazole is expensive and carries a meaningful side-effect profile, which is one of the reasons that having a topical option is valuable: it delivers drug directly to the site of infection while largely avoiding those broader risks.1Clinical Ophthalmology. Clinical utility of voriconazole eye drops in ophthalmic fungal keratitis
Resistance Patterns and Why They Matter
Not all fungi are equally susceptible to voriconazole. A UK study testing antifungal susceptibility of fungal isolates from corneas and contact lenses found that about 81% of isolates were susceptible to voriconazole, compared to roughly 95% for natamycin. The organisms most likely to resist voriconazole were Fusarium species: only about 60% of Fusarium isolates tested susceptible to voriconazole, versus 100% for natamycin. No Aspergillus isolates in that study were highly resistant to voriconazole.10Nature. Antifungal susceptibility profiles for fungal isolates from corneas and contact lenses in the United Kingdom
These resistance figures explain the clinical trial results discussed earlier. Fusarium is inherently less sensitive to voriconazole, which is why natamycin outperforms it so clearly in Fusarium keratitis. For Aspergillus and most Candida species, voriconazole maintains solid activity and remains a reliable treatment choice. Knowing which fungus is causing the infection, through corneal scraping and culture, is therefore one of the most important steps in deciding whether voriconazole drops will be effective.
Beyond Eye Drops: Intrastromal and Intravitreal Injection
When topical drops are not enough, voriconazole can be delivered more directly. In cases of deep fungal keratitis that fails to respond to standard topical therapy, ophthalmologists may inject a small amount of voriconazole directly into the corneal stroma (the middle layer of the cornea). A case series evaluating this technique in patients with recalcitrant infections found it to be a useful treatment option for managing deep fungal keratitis that had not improved with surface-level drops alone.11PubMed. Evaluation of intrastromal voriconazole injection in recalcitrant deep fungal keratitis: case series
For infections that have spread inside the eye (fungal endophthalmitis), voriconazole can be injected directly into the vitreous cavity, the gel-filled space behind the lens. Studies in animal models have shown that an intravitreal injection produces high initial drug levels in the vitreous, though concentrations drop quickly: from a high level at one hour after injection down to much lower levels within 16 hours.12Investigative Ophthalmology & Visual Science. Clearance of Intravitreal Voriconazole The rapid clearance means that repeat injections may be necessary, and systemic antifungal therapy is often used alongside the injection. Reassuringly, the rabbit eyes studied showed no retinal damage, hemorrhage, or detachment from the injection itself.12Investigative Ophthalmology & Visual Science. Clearance of Intravitreal Voriconazole
Use in Children
Fungal keratitis in children is rare but can be particularly challenging because young patients may not report symptoms as clearly and may be less cooperative with frequent eye drop schedules. Published reviews note that voriconazole is considered a good choice for pediatric fungal keratitis because of its deep tissue penetration and activity against organisms that may resist other antifungals. However, the same pattern seen in adults holds true: when studies have compared voriconazole to natamycin in children, natamycin tends to produce better visual acuity and faster healing of corneal ulcers, with no significant difference in scar size or perforation rates.13Archives of Pediatric Infectious Diseases. Management of Fungal Keratitis in Pediatric Patients In practice, treatment decisions for children are guided by the same principles as for adults: identify the causative organism if possible, and choose the antifungal best suited to it.
Practical Considerations During Treatment
If you are prescribed voriconazole eye drops for a fungal corneal infection, a few things are worth knowing. First, the dosing frequency is often aggressive in the early days. Some regimens call for drops every hour around the clock for the first 48 hours, then tapering gradually as the infection responds. This intense schedule reflects the fact that each drop delivers drug only to the corneal surface, and the drug clears from the eye relatively quickly. Missing doses or shortening the course can allow the fungus to regain ground.
Second, treatment duration is typically long. Fungal infections of the cornea heal slowly compared to bacterial ones, and courses of four to six weeks are common. Some patients require even longer treatment. You will likely have frequent follow-up visits so your ophthalmologist can monitor the size and depth of the infection, check for complications like perforation, and adjust therapy if the organism turns out to be resistant.
Third, the drops themselves are compounded products, which means availability depends on having a pharmacy equipped and willing to prepare them. This can be a logistical hurdle, especially in settings without a hospital compounding pharmacy nearby. The cost of the raw material (injectable voriconazole) adds another layer: systemic voriconazole is expensive, and even the small amount needed for eye drops can carry a meaningful price tag.1Clinical Ophthalmology. Clinical utility of voriconazole eye drops in ophthalmic fungal keratitis
Open Questions in the Field
Despite solid evidence that voriconazole eye drops work for certain types of fungal keratitis, researchers have noted several areas that still need attention. There is limited data on whether voriconazole drops could serve as a first-line, standalone treatment rather than being combined with other antifungals or used as a backup when natamycin fails. Questions also remain about whether higher concentrations (above 1%) could improve outcomes for deep or stubborn infections, and about what the optimal dosing frequency actually is.1Clinical Ophthalmology. Clinical utility of voriconazole eye drops in ophthalmic fungal keratitis
The broader challenge is that fungal keratitis is not common enough in wealthy countries to attract large pharmaceutical investment in new topical antifungal products. Most of the disease burden falls on agricultural workers in tropical and subtropical regions, where access to compounding pharmacies, laboratory diagnosis, and specialist eye care is often limited. For these populations, natamycin’s advantages are not just clinical but practical: it is commercially available off the shelf, while voriconazole drops require custom preparation and cold storage. Until a commercially manufactured voriconazole eye drop reaches the market, the compounded version will remain the only topical option for cases where this drug’s spectrum is genuinely needed.